Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

<p>Read sequencing depth by sample</p>

Збережено в:

Бібліографічні деталі
Автор:	N. Ari Wijetunga (15056183) (author)
Інші автори:	Alexander G. Goglia (15056186) (author), Nils Weinhold (15056189) (author), Michael F. Berger (15048171) (author), Michael Cislo (15056192) (author), Daniel S. Higginson (14949837) (author), Kiana Chabot (15056195) (author), Ahmed M. Osman (15056198) (author), Lauren Schaff (15056201) (author), Elena Pentsova (15056204) (author), Alexandra M. Miller (15056207) (author), Simon N. Powell (15056210) (author), Adrienne Boire (14944705) (author), Jonathan T. Yang (15056213) (author)
Опубліковано:	2025
Предмети:	Cancer Therapeutic Research and Development Methods and Technology CNS Cancers Gene Technologies High-throughput sequencing Liquid Biopsy Radiation Oncology Molecular targets of radiation response Translational Research
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
за авторством: N. Ari Wijetunga (15056183)
Опубліковано: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
за авторством: N. Ari Wijetunga (15056183)
Опубліковано: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
за авторством: N. Ari Wijetunga (15056183)
Опубліковано: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Figure S1 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Figure S2 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Figure S3 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Figure S5 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
за авторством: Rumani Singh (17141575)
Опубліковано: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
за авторством: Mengjie Zhao (14845174)
Опубліковано: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
за авторством: Mengjie Zhao (14845174)
Опубліковано: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
за авторством: Mengjie Zhao (14845174)
Опубліковано: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
за авторством: Mengjie Zhao (14845174)
Опубліковано: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
за авторством: Mengjie Zhao (14845174)
Опубліковано: (2025)

Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
за авторством: Amy C. Degnim (15106462)
Опубліковано: (2025)

Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
за авторством: Amy C. Degnim (15106462)
Опубліковано: (2025)

Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
за авторством: Amy C. Degnim (15106462)
Опубліковано: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
за авторством: Bouchra Tawk (15389486)
Опубліковано: (2025)

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
за авторством: Gonzalo Rodriguez-Berriguete (15056057)
Опубліковано: (2025)

Immunohistochemical staining for PHLDA3, APOE, and CPE in irradiated brain tissues.
за авторством: Jing Liu (38537)
Опубліковано: (2025)

Supplementary Table 1 from Monounsaturated and Diunsaturated Fatty Acids Sensitize Cervical Cancer to Radiation Therapy
за авторством: Naoshad Muhammad (14960127)
Опубліковано: (2025)

Supplementary Table 2 from Monounsaturated and Diunsaturated Fatty Acids Sensitize Cervical Cancer to Radiation Therapy
за авторством: Naoshad Muhammad (14960127)
Опубліковано: (2025)

Global Wildfire Brown Carbon Simulation Results: Supporting Data for "Strong Shortwave Absorption by Wildfire Brown Carbon from Global Observations and Modeling"
за авторством: Lulu Xu (21634004)
Опубліковано: (2025)

2024 Meteorological Data, Upper Chesapeake Bay, MarineGEO, Smithsonian Environmental Research Center
за авторством: Sam Benson (17684957)
Опубліковано: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
за авторством: Michelle L. Mierzwa (14963463)
Опубліковано: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
за авторством: Sami Belhadj (15052341)
Опубліковано: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
за авторством: Cloud P. Paweletz (14960112)
Опубліковано: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
за авторством: Whitney L. Hensing (16461978)
Опубліковано: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
за авторством: Stephanie Lheureux (16797697)
Опубліковано: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
за авторством: Stephanie Lheureux (16797697)
Опубліковано: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
за авторством: Stephanie Lheureux (16797697)
Опубліковано: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
за авторством: Stephanie Lheureux (16797697)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lcmv564kqrh40609qmogncov62